(NYSE: RDY) Dr Reddys Laboratories's forecast annual revenue growth rate of 9.08% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 1.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.03%.
Dr Reddys Laboratories's revenue in 2023 is $2,734,579,081.On average, 2 Wall Street analysts forecast RDY's revenue for 2023 to be $494,370,314,416, with the lowest RDY revenue forecast at $492,756,982,236, and the highest RDY revenue forecast at $495,983,813,022. On average, 2 Wall Street analysts forecast RDY's revenue for 2024 to be $545,314,265,350, with the lowest RDY revenue forecast at $538,871,920,736, and the highest RDY revenue forecast at $551,756,776,391.
In 2025, RDY is forecast to generate $584,843,899,431 in revenue, with the lowest revenue forecast at $581,909,645,287 and the highest revenue forecast at $587,778,320,000.